Advertisement
Advertisement
IRWD
Ironwood Pharmaceuticals, Inc. - Class A
3.48
USDSponsored
+0.11
+3.15%
Mar 17, 09:46 UTC -4
Open
IRWD Earnings Reports
Positive Surprise Ratio
IRWD beat 21 of 40 last estimates.
53%
Next Report
Date of Next Report
May 05, 2026
Estimate for Q1 26 (Revenue/ EPS)
$93.93M
/$0.24
Implied change from Q4 25 (Revenue/ EPS)
+96.88%
/-2500.00%
Implied change from Q1 25 (Revenue/ EPS)
+128.30%
/-271.43%
Ironwood Pharmaceuticals, Inc. - Class A earnings per share and revenue
On Feb 25, 2026, IRWD reported earnings of -0.01 USD per share (EPS) for Q4 25, missing the estimate of 0.01 USD, resulting in a -198.04% surprise. Revenue reached 47.71 million, compared to an expected 51.95 million, with a -8.17% difference. The market reacted with a -2.39% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 4 analysts forecast an EPS of 0.24 USD, with revenue projected to reach 93.93 million USD, implying an decrease of -2500.00% EPS, and increase of 96.88% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Oruka Therapeutics, Inc. Common Stock
Report Date
Mar 12, 2026 For Q4 25
Estimate
-$0.64
Actual
-$0.45
Surprise
+29.69%
Savara Inc.
Report Date
Mar 13, 2026 For Q4 25
Estimate
-$0.12
Actual
-$0.13
Surprise
-8.15%
Nektar Therapeutics
Report Date
Mar 12, 2026 For Q4 25
Estimate
-$2.52
Actual
-$1.78
Surprise
+29.47%
Lyell Immunopharma, Inc. Common Stock
Report Date
Mar 12, 2026 For Q4 25
Estimate
-$2.27
Actual
-$7.50
Surprise
-229.53%
Tonix Pharmaceuticals Holding Corp.
Report Date
Mar 12, 2026 For Q4 25
Estimate
-$3.25
Actual
-$3.98
Surprise
-22.32%
Century Therapeutics, Inc. Common Stock
Report Date
Mar 12, 2026 For Q4 25
Estimate
-$0.28
Actual
-$0.22
Surprise
+23.88%
Korro Bio, Inc. Common Stock
Report Date
Mar 12, 2026 For Q4 25
Estimate
-$2.10
Actual
-$1.65
Surprise
+21.74%
Verrica Pharmaceuticals Inc. Common Stock
Report Date
Mar 11, 2026 For Q4 25
Estimate
-$0.81
Actual
-$0.46
Surprise
+43.22%
Champions Oncology, Inc.
Report Date
Mar 12, 2026 For Q3 26
Estimate
$0.09
Actual
-$0.02
Surprise
-121.79%
Guardian Pharmacy Services, Inc.
Report Date
Mar 11, 2026 For Q4 25
Estimate
$0.25
Actual
$0.33
Surprise
+29.41%
FAQ
What were Ironwood Pharmaceuticals, Inc. - Class A's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Ironwood Pharmaceuticals, Inc. - Class A reported EPS of -$0.01, missing estimates by -198.04%, and revenue of $47.71M, -8.17% below expectations.
How did the market react to Ironwood Pharmaceuticals, Inc. - Class A's Q4 2025 earnings?
The stock price moved down -2.39%, changed from $4.61 before the earnings release to $4.50 the day after.
When is Ironwood Pharmaceuticals, Inc. - Class A expected to report next?
The next earning report is scheduled for May 05, 2026.
What are the forecasts for Ironwood Pharmaceuticals, Inc. - Class A's next earnings report?
Based on 4
analysts, Ironwood Pharmaceuticals, Inc. - Class A is expected to report EPS of $0.24 and revenue of $93.93M for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement